Haemonetics Q3 fiscal 2023 adjusted EPS $0.82, revenue $298.1M; raises full-year guidance

HAEMONETICS CORP

2023-Q3 EPS reported $1.67 revenue$864,244,000

Q3 revenue $298.1M (+2.1% reported, -0.1% organic); GAAP EPS $0.37, adjusted EPS $0.82 vs $0.73 prior year.
Plasma revenue up 3% reported but down 5% organic; Hospital revenue up 12% reported (+7% organic).
Fiscal 2023 revenue guidance raised to $1.195B-$1.205B; adjusted EPS guidance raised to $3.45-$3.55.
Nine-month revenue $891.2M (+5.2% reported, +5.9% organic); operating cash flow $157.3M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HAEMONETICS CORP reported financial results for third quarter and nine months ended December 31, 2022.

Period: third quarter and nine months ended December 31, 2022
Result: reported results

Exact text from the filing

On February 7, 2023, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

HAEMONETICS CORP filing history →

Source: SEC EDGAR

accession 0000313143-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.